PDCD1 and small cell lung carcinoma: Clinical trials have demonstrated that blockade of the interactions between PD-1 and PD-L1 enhances anticancer immunity in SCLC, thus leading to a potentially-improved progression-free survival (PFS) and OS [22,23,24].